Current evidence for the risk of PR prolongation, QRS widening, QT prolongation, from lopinavir, ritonavir, atazanavir, and saquinavir: A systematic review

BACKGROUND: Lopinavir, ritonavir, atazanavir, and saquinavir had been reportedly used or suggested for coronavirus disease 2019 (COVID-19) treatment. They may cause electrocardiography changes. We aim to evaluate risk of PR prolongation, QRS widening, and QT prolongation from lopinavir, ritonavir, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ridjab, Denio A., Ivan, Ignatius, Budiman, Fanny, Juliawati, Dwi Jani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
3400
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8341216/
https://www.ncbi.nlm.nih.gov/pubmed/34397829
http://dx.doi.org/10.1097/MD.0000000000026787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8341216/
https://www.ncbi.nlm.nih.gov/pubmed/34397829
http://dx.doi.org/10.1097/MD.0000000000026787

Ejemplares similares